These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
278 related articles for article (PubMed ID: 33747147)
21. Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments. Solomon B; Young RJ; Rischin D Semin Cancer Biol; 2018 Oct; 52(Pt 2):228-240. PubMed ID: 29355614 [TBL] [Abstract][Full Text] [Related]
22. NICO Phase II clinical trial - focus on an emerging immunotherapy strategy for the adjuvant treatment of locally-advanced oral cancers. Brooker RC; Schache AG; Sacco JJ Br J Oral Maxillofac Surg; 2021 Oct; 59(8):959-962. PubMed ID: 34325944 [TBL] [Abstract][Full Text] [Related]
23. Immune checkpoint inhibitors for head and neck squamous cell carcinoma: Current landscape and future directions. Kao HF; Lou PJ Head Neck; 2019 Oct; 41 Suppl 1():4-18. PubMed ID: 31573752 [TBL] [Abstract][Full Text] [Related]
24. Biomarkers for immunotherapy response in head and neck cancer. Gavrielatou N; Doumas S; Economopoulou P; Foukas PG; Psyrri A Cancer Treat Rev; 2020 Mar; 84():101977. PubMed ID: 32018128 [TBL] [Abstract][Full Text] [Related]
25. Emerging immune checkpoint inhibitors for the treatment of head and neck cancers. Green SE; McCusker MG; Mehra R Expert Opin Emerg Drugs; 2020 Dec; 25(4):501-514. PubMed ID: 33196319 [No Abstract] [Full Text] [Related]
26. Evolution of treatment and high-risk features in resectable locally advanced Head and Neck squamous cell carcinoma with special reference to extracapsular extension of nodal disease. Krstevska V J BUON; 2015; 20(4):943-53. PubMed ID: 26416042 [TBL] [Abstract][Full Text] [Related]
34. Checkpoint immunotherapy in head and neck cancers. Zolkind P; Uppaluri R Cancer Metastasis Rev; 2017 Sep; 36(3):475-489. PubMed ID: 28836124 [TBL] [Abstract][Full Text] [Related]
35. Immuno-oncology in head and neck squamous cell cancers: News from clinical trials, emerging predictive factors and unmet needs. Cavalieri S; Rivoltini L; Bergamini C; Locati LD; Licitra L; Bossi P Cancer Treat Rev; 2018 Apr; 65():78-86. PubMed ID: 29574334 [TBL] [Abstract][Full Text] [Related]
37. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. Zandberg DP; Algazi AP; Jimeno A; Good JS; Fayette J; Bouganim N; Ready NE; Clement PM; Even C; Jang RW; Wong S; Keilholz U; Gilbert J; Fenton M; Braña I; Henry S; Remenar E; Papai Z; Siu LL; Jarkowski A; Armstrong JM; Asubonteng K; Fan J; Melillo G; Mesía R Eur J Cancer; 2019 Jan; 107():142-152. PubMed ID: 30576970 [TBL] [Abstract][Full Text] [Related]
38. [Immunotherapy of head and neck tumors: Highlights of the ASCO Meeting 2015]. Laban S; Doescher J; Schuler PJ; Bullinger L; Brunner C; Veit JA; Hoffmann TK HNO; 2015 Sep; 63(9):612-9. PubMed ID: 26319429 [TBL] [Abstract][Full Text] [Related]
39. Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting. Bauman JE; Cohen E; Ferris RL; Adelstein DJ; Brizel DM; Ridge JA; O'Sullivan B; Burtness BA; Butterfield LH; Carson WE; Disis ML; Fox BA; Gajewski TF; Gillison ML; Hodge JW; Le QT; Raben D; Strome SE; Lynn J; Malik S Cancer; 2017 Apr; 123(7):1259-1271. PubMed ID: 27906454 [TBL] [Abstract][Full Text] [Related]
40. Immunotherapy in head and neck cancer: aiming at EXTREME precision. Szturz P; Vermorken JB BMC Med; 2017 Jun; 15(1):110. PubMed ID: 28571578 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]